Skip to main content

Advertisement

Table 2 Diagnosis and treatment

From: Value of transfusion independence in severe aplastic anemia from patients’ perspectives – a discrete choice experiment

  All Respondents (N = 30)
First Diagnosed with SAA, N (%)
 2 or fewer years ago 15 (50.0%)
 3 to 4 years ago 8 (26.7%)
 5 or more years ago 7 (23.3%)
Symptoms and Complications,a N (%)
 Fatigue (interferes with daily activities like work and school) 26 (86.7%)
 Infections requiring hospitalization 16 (53.3%)
 Bleeding 16 (53.3%)
Number of Treatments Received after SAA Diagnosis, N (%)
 1–3 13 (43.3%)
 4–5 10 (33.3%)
 6 or more 7 (23.3%)
Types of Treatments Received after SAA Diagnosis,a N (%)
 Immunosuppressive therapies 29 (96.7%)
 Steroids 24 (80.0%)
 Targeted therapy 17 (56.7%)
 Antibiotics 17 (56.7%)
 Antifungals 14 (46.7%)
 Bone marrow transplant 10 (33.3%)
 Erythropoiesis-stimulating agents/growth factors 9 (30.0%)
Red Blood Cell or Whole Blood Transfusions Frequency, N (%)
 Have not received red blood cell transfusions in the past 3 months 16 (53.3%)
 Once every 31–90 days 4 (13.3%)
 Once every 15–30 days 5 (16.7%)
 Once every 8–14 days 5 (16.7%)
 Once per week 0 (0.0%)
 More than once per week 0 (0.0%)
Platelet Transfusions Frequency, N (%)
 Have not received platelet transfusions in the past 3 months 21 (70.0%)
 Once every 31–90 days 3 (10.0%)
 Once every 15–30 days 1 (3.3%)
 Once every 8–14 days 2 (6.7%)
 Once per week 3 (10.0%)
 More than once per week 0 (0.0%)
Received Iron Chelation Therapy, N (%) 11 (36.7%)
  1. aRespondents were allowed to select multiple values for symptoms and complications, and treatments received, thus counts and percentages may sum to more than the total N or 100%